Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343291 · ClinicalTrials.gov registry record · Phase 2
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00343291 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 121 participants.
The verdict
NCT00343291, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Interventions
- DRUG Carboplatin
- BIOLOGICAL Cetuximab
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343291
The ClinicalTrials.gov registry entry for NCT00343291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00343291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343291 about?
NCT00343291 is a clinical study titled "A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC". The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxe...
What is the current status of trial NCT00343291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2006-12. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00343291?
The interventions under investigation include: Carboplatin (DRUG), Cetuximab (BIOLOGICAL), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00343291?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.